4726 Stock Overview
Develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Mycenax Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$61.50 |
| 52 Week High | NT$63.00 |
| 52 Week Low | NT$33.85 |
| Beta | 1.0 |
| 11 Month Change | 42.36% |
| 3 Month Change | 65.32% |
| 1 Year Change | 48.37% |
| 33 Year Change | 47.48% |
| 5 Year Change | 186.71% |
| Change since IPO | 247.46% |
Recent News & Updates
Shareholder Returns
| 4726 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 25.1% | -0.1% | 4.9% |
| 1Y | 48.4% | -1.0% | 33.1% |
Return vs Industry: 4726 exceeded the TW Biotechs industry which returned -1% over the past year.
Return vs Market: 4726 exceeded the TW Market which returned 33.1% over the past year.
Price Volatility
| 4726 volatility | |
|---|---|
| 4726 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4726's share price has been volatile over the past 3 months.
Volatility Over Time: 4726's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 387 | Pei-Jiun Chen | www.mycenax.com.tw |
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies.
Mycenax Biotech Inc. Fundamentals Summary
| 4726 fundamental statistics | |
|---|---|
| Market cap | NT$12.66b |
| Earnings (TTM) | -NT$577.49m |
| Revenue (TTM) | NT$594.42m |
21.3x
P/S Ratio-21.9x
P/E RatioIs 4726 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4726 income statement (TTM) | |
|---|---|
| Revenue | NT$594.42m |
| Cost of Revenue | NT$952.11m |
| Gross Profit | -NT$357.68m |
| Other Expenses | NT$219.81m |
| Earnings | -NT$577.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.81 |
| Gross Margin | -60.17% |
| Net Profit Margin | -97.15% |
| Debt/Equity Ratio | 27.0% |
How did 4726 perform over the long term?
See historical performance and comparison